Incannex Healthcare Inc. IXHL
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Incannex Healthcare Inc. (IXHL) is a healthcare company listed in the US with a market value of about $25M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -149%.
About Incannex Healthcare
Incannex Healthcare is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $604884 in 2020 to $86000 in 2025, a decline of about 32.3% a year. It was profitable in 0 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $86000 | $12000 | — | — | $2M | $604884 |
| Net income | -$19M | -$47M | -$18M | -$49M | -$15M | -$11M | -$5M |
| Free cash flow | -$13M | -$13M | -$16M | -$11M | — | — | — |
| EPS (diluted) | $-1.54 | $-3.74 | $-1.47 | $-3.89 | $-1.19 | $-0.91 | $-0.37 |
| Net margin | — | -54517.4% | -153800.0% | — | — | -599.3% | -776.6% |
| ROIC | -34.1% | -174.3% | -204.8% | -183.8% | — | -104.8% | -98.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $18.12, 820% above the current price; targets range from $17.49 to $18.76; the consensus rating is “none”; expected EPS is $-2.23 for the fiscal year ending June 30, 2027.
Frequently asked questions
Does Incannex Healthcare pay a dividend?
Not currently.
Is Incannex Healthcare a good stock to buy?
We do not give buy or sell advice. Incannex Healthcare scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.